Switch theme
Sign up to access all valuation multiples
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
1989
357
LTM Revenue $251M
LTM EBITDA $59.1M
$2.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vericel has a last 12-month revenue of $251M and a last 12-month EBITDA of $59.1M.
In the most recent fiscal year, Vericel achieved revenue of $237M and an EBITDA of $16.6M.
Vericel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vericel valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $198M | $237M | XXX | XXX | XXX |
| Gross Profit | $110M | $136M | XXX | XXX | XXX |
| Gross Margin | 56% | 57% | XXX | XXX | XXX |
| EBITDA | $2.9M | $16.6M | XXX | XXX | XXX |
| EBITDA Margin | 1% | 7% | XXX | XXX | XXX |
| Net Profit | -$16.7M | -$3.2M | XXX | XXX | XXX |
| Net Margin | -8% | -1% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vericel's stock price is $41.
Vericel has current market cap of $2.1B, and EV of $2.0B.
See Vericel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.0B | $2.1B | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vericel has market cap of $2.1B and EV of $2.0B.
Vericel's trades at 8.2x LTM EV/Revenue multiple, and 34.7x LTM EBITDA.
Analysts estimate Vericel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vericel and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.0B | XXX | XXX | XXX |
| EV/Revenue | 8.6x | XXX | XXX | XXX |
| EV/EBITDA | 123.3x | XXX | XXX | XXX |
| P/E | 199.5x | XXX | XXX | XXX |
| P/E/Growth | 2.1x | XXX | XXX | XXX |
| EV/FCF | -352.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVericel's NTM/LTM revenue growth is 22%
Vericel's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Vericel's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vericel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vericel and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 481% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 29% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 71% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vericel acquired XXX companies to date.
Last acquisition by Vericel was XXXXXXXX, XXXXX XXXXX XXXXXX . Vericel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vericel founded? | Vericel was founded in 1989. |
| Where is Vericel headquartered? | Vericel is headquartered in United States of America. |
| How many employees does Vericel have? | As of today, Vericel has 357 employees. |
| Who is the CEO of Vericel? | Vericel's CEO is Mr. Dominick C. Colangelo. |
| Is Vericel publicy listed? | Yes, Vericel is a public company listed on NAS. |
| What is the stock symbol of Vericel? | Vericel trades under VCEL ticker. |
| When did Vericel go public? | Vericel went public in 1997. |
| Who are competitors of Vericel? | Similar companies to Vericel include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Vericel? | Vericel's current market cap is $2.1B |
| What is the current revenue of Vericel? | Vericel's last 12-month revenue is $251M. |
| What is the current EBITDA of Vericel? | Vericel's last 12-month EBITDA is $59.1M. |
| What is the current EV/Revenue multiple of Vericel? | Current revenue multiple of Vericel is 8.2x. |
| What is the current EV/EBITDA multiple of Vericel? | Current EBITDA multiple of Vericel is 34.7x. |
| What is the current revenue growth of Vericel? | Vericel revenue growth between 2023 and 2024 was 20%. |
| Is Vericel profitable? | Yes, Vericel is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
